# Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

> **NCT01938248** · PHASE4 · COMPLETED · sponsor: **Population Health Research Institute** · enrollment: 4012 (actual)

## Conditions studied

- Atrial Fibrillation
- Stroke

## Interventions

- **DRUG:** Apixaban
- **DRUG:** aspirin

## Key facts

- **NCT ID:** NCT01938248
- **Lead sponsor:** Population Health Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2023-10-27
- **Final completion:** 2023-11-03
- **Target enrollment:** 4012 (ACTUAL)
- **Last updated:** 2023-11-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01938248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01938248, "Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01938248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*